ダウンロード数: 202
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
aja2012.107.pdf | 392.13 kB | Adobe PDF | 見る/開く |
タイトル: | Overexpression of ETS-1 is associated with malignant biological features of prostate cancer. |
著者: | Li, Bo Shimizu, Yosuke Kobayashi, Takashi Terada, Naoki Yoshimura, Koji Kamba, Tomomi Mikami, Yoshiki Inoue, Takahiro Nishiyama, Hiroyuki Ogawa, Osamu |
著者名の別形: | 清水, 洋祐 |
キーワード: | prostate cancer ETS-1 immunohistochemistry castration resistant |
発行日: | Nov-2012 |
出版者: | Nature Publishing Group |
誌名: | Asian journal of andrology |
巻: | 14 |
号: | 6 |
開始ページ: | 860 |
終了ページ: | 863 |
抄録: | E26 transformation-specific-1 (ETS-1), an ETS family transcription factor, has been reported to play an important role in a variety of physiological and pathological processes, but clinical implications of ETS-1 expression in prostate cancer (PCa), particularly high-risk cases, including response to androgen-deprivation therapy (ADT) have yet to be elucidated. We examined the expression of ETS-1 using immunohistochemical staining of paraffin-embedded prostate carcinoma tissue obtained by needle biopsy from 69 mostly advanced PCa patients. ETS-1 expression was compared with the clinicopathological characteristics of the 69 patients, including 25 who underwent ADT as a primary treatment. As a result, PCa patients with higher expression of ETS-1 were significantly more likely to be of high stage and high Gleason score (P<0.05). There was no significant association between ETS-1 expression and the initial prostate-specific antigen (PSA) level. In the 25 patients treated by ADT, the staining score for ETS-1 was significantly associated with rapid development of castration-resistant disease within 24 months (P<0.05), whereas the Gleason score and PSA level were not. In conclusion, increased ETS-1 expression was associated with a higher stage, higher Gleason score and shorter time to castration-resistant progression. These data suggest that immunostaining for ETS-1 could be a molecular marker for predicting a poor clinical outcome for PCa patients, particularly those with high-risk disease. |
著作権等: | © 2013 SIMM, CAS and SJTU この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。 This is not the published version. Please cite only the published version. |
URI: | http://hdl.handle.net/2433/175241 |
DOI(出版社版): | 10.1038/aja.2012.107 |
PubMed ID: | 23064684 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。